Best Practice & Research Clinical Rheumatology
Volume 23, Issue 6 , Pages 755-768 , December 2009

A perspective on male osteoporosis

  • Neil Binkley

      Affiliations

    • Corresponding Author InformationSuite 100, 2870 University Avenue, Madison, WI 53705, USA. Tel.: +1 608 265 6410; fax: +1 608 265 6409.

References 

  1. Anonymous . Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1990;90:107–110
  2. Nguyen TV, Eisman JA, Kelly PJ, et al. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996;144:255–263
  3. Kiebzak GM, Bienart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162:2217–2222
  4. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878–882
  5. Pande I, Scott DL, O'Neill TW, et al. Quality of life, morbidity and mortality after low trauma hip fracture in men. Annals of Rheumatic Disease. 2006;65:87–92
  6. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int. 2004;15:108–112
  7. Wehren LE, Hawkes WG, Orwig DL, et al. Gender differences in mortality after hip fracture: the role of infection. J Bone Miner Res. 2003;18:2231–2237
  8. Riggs BL, Melton LJI, Robb RA, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res. 2004;19:1945–1954
  9. Burger H, De Laet CEDH, Van Daele PLA, et al. Risk factors for increased bone loss in an elderly population. Am J Epidemiol. 1998;147:871–879
  10. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164
  11. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91:1336–1344
  12. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29:441–464
  13. Clarke BL, Khosla S. Androgens and bone. Steroids. 2009;74:296–305
  14. Compston J. Secondary causes of osteoporosis in men. Calcif Tissue Int. 2001;69:193–195
  15. Kamel HK. Male osteoporosis: new trends in diagnosis and therapy. Drugs Aging. 2005;22:741–748
  16. Vanderschueren D, Boonen S, Bouillon R. Osteoporosis and osteoporotic fractures in men: A clinical perspective. Baillieres Clin Endocrinol Metab. 2000;14:299–315
  17. Pernow Y, Hauge EM, Linder K, et al. Bone histomorphometry in male idiopathic osteoporosis. Calcif Tissue Int. 2009;84:430–438
  18. Kanis JA, Melton LJI, Christiansen C, et al. Perspective The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–1141
  19. Leslie WD, Adler RA, Fuleihan GE, et al. Application of the 1994 WHO Classification to Populations other than postmenopausal Caucasian women: The 2005 ISCD Official Positions. J Clin Densitom. 2006;9:22–30
  20. Cummings SR, Cawthon PM, Ensrud KE, et al. BMD and risk of hip and nonvertebral fractures in older men: A prospective study and comparison with older women. J Bone Miner Res. 2006;21:1550–1556
  21. Liu G, Peacock M, Eilam O, et al. Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int. 1997;7:564–569
  22. Melton LJI, Atkinson EJ, O'Connor MK, et al. Bone density and fracture risk in men. J Bone Miner Res. 1998;13:1915–1923
  23. Baim S, Binkley N, Bilezikian JP, et al. Official positions of the International Society for Clinical Densitometry and Executive summary of the 2007 ISCD position development conference. J Clin Densitom. 2008;11:75–91
  24. Vallarta-Ast N, Krueger D, Binkley N. An evaluation of forearm BMD measurement for diagnosis and treatment monitoring in men. J Bone Miner Res. 2007;22(suppl 1):S300
  25. Simonelli C, Adler RA, Blake GM, et al. Dual-energy x-ray absorptiometry technical issues: The 2007 ISCD Official Positions. J Clin Densitom. 2008;11:109–122
  26. Kanis JA, Gluer C-C. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int. 2000;11:192–202
  27. Papaioannou A, Kennedy CC, Ioannidis G, et al. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2008;19:581–587
  28. Cadarette SM, Gignac MAM, Jaglal SB, et al. Access to osteoporosis treatment is critically linked to access to dual-energy x-ray absorptiometry testing. Med Care. 2007;45:896–901
  29. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414–2419
  30. Kanis JA, Johnell O, Oden A, et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–397
  31. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003;33:522–532
  32. Dawson-Hughes B, Tosteson ANA, Melton LJI, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449–458
  33. Kanis JA, Johnell O, Oden A, et al. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int. 2005;16:6–14
  34. Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone. 2004;34:195–202
  35. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–1046
  36. Lu Y, Fuerst T, Hui S, et al. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int. 2001;12:438–444
  37. Sandhu SK, Nguyen ND, Center JR, et al. Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram. Osteoporos Int; in press.
  38. Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148:680–684
  39. Anonymous. Clincian's Guide to Prevention and Treatment of Osteoporosis. 2008: in press.
  40. Liu H, Paige NM, Goldzweig CL, et al. Screening for osteoporosis in men: A systematic review for an American College of Physicians Guideline. Ann Intern Med. 2008;148:685–701
  41. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J. 2002;167:S1–S34
  42. Lim LS, Hoeksema LJ, Sherin K. Screening for osteoporosis in the adult U.S. population ACPM position statement on preventive practice. Am J Prev Med. 2009;36:366–375
  43. Espallargues M, CSampietro-Colom L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: A systematic review of the literature. Osteoporos Int. 2001;12:811–822
  44. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007;298:629–637
  45. Holick MF. Vitamin D: A millennium perspective. J Cell Biochem. 2003;88:296–307
  46. Orwoll E, Nielson CM, Marshall LM, et al. Vitamin D deficiency in older men. J Clin Endocrinol Metab. 2009;94:1214–1222
  47. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77:204–210
  48. Meier C, Nguyen TV, Center JR, et al. Bone resorption and osteoporotic fractures in elderly men: The Dubbo osteoporosis epidemiology study. J Bone Miner Res. 2005;20:579–587
  49. Binkley N & Buehring B. Beyond FRAX: It is time to consider sarco-osteopenia. J Clin Densitom 2009: in press.
  50. Anonymous . the American Geriatrics Society, British Geriatrics Society and American Academy of Orthopedic Surgeons. Guideline for the prevention of falls in older persons. Annals of Long-Term Care. 2001;11:42–54
  51. Heaney RP. Phosphorus nutrition and the treatment of osteoporosis. Mayo Clin Proc. 2004;79:91–97
  52. Levis S, Gomez A, Jimenez C, et al. Vitamin D deficiency and seasonal variation in an adult south Florida population. J Clin Endocrinol Metab. 2005;90:1557–1562
  53. Ginde AA, Liu MC, Camargo CA. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169:626–632
  54. Ensrud KE, Taylor BC, Paudel ML, et al. Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men. J Clin Endocrinol Metab. 2009;94:2773–2780
  55. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713–716
  56. Heaney RP. Barriers to optimizing vitamin D3 intake for the elderly. J Nutr. 2006;136:1123–1125
  57. Bischoff-Ferrari HA. Vitamin D in fracture prevention land muscle function and fall prevention. Clin Rev Bone Miner Metabol. 2009;7:107–112
  58. Hijazi RA, Cunningham GR. Andropause: Is androgen replacement therapy indicated for the aging male?. Annual Review of Medicine. 2005;56:117–137
  59. Anonymous . American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocrine Practice. 2002;8:439–456
  60. Allan CA, McLachlan RI. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol (Oxf). 2004;60:653–670
  61. Wald M, Meacham RB, Ross LS, et al. Testosterone replacement therapy for older men. J Androl. 2006;27:126–132
  62. Orwoll ES, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604–610
  63. Ringe JD, Dorst A, Faber H, et al. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004;24:110–113
  64. Ringe J, Faber H, Salem M, et al. Risedronate therapy reduces the risk of new vertebral fractures by 60% in osteoporotic men with osteoporosis within 1 year. J Bone Miner Res. 2004;19(supplement 1):s441
  65. Ringe JD, Farahmand P, Faber H, et al. Sustained efficacy of risedroante in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009;29:311–315
  66. Reid DM, Adami S, Devogelaer JP, et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001;69:242–247
  67. Miller PD, Schnitzer T, Emkey R, et al. Weekly oral alendronic acid in male osteoporosis. Clinical Drug Investigation. 2004;24:333–341
  68. Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: Results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009;24:719–725
  69. Lyles KW, Colon-Emeric C, Magaziner J, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809
  70. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–2012
  71. Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med. 2005;165:1743–1748
  72. Bauer DC, Orwoll E. Quality indicators for management of osteoporosis. Ann Intern Med. 2002;137:621–622
  73. Orwoll E, Scheele W, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9–17
  74. Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: An analysis by gender and menopausal status. Osteoporos Int. 2009;online first
  75. Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006;91:2882–2887
  76. Finkelstein JS, Hayes A, Hunzelman JL, et al. The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis. N Engl J Med. 2003;349:1216–1226
  77. Trovas GP, Lyritis G, Galanos A, et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: Effects on bone mineral density and bone markers. J Bone Miner Res. 2002;17:521–527
  78. Toth E, Csupor E, Meszaros S, et al. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures - An open label study. Bone. 2005;36:47–51
  79. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197–213
  80. Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int. 2005;16:953–962
  81. Cardarette SM, Katz JN, Brookhart A, et al. Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. J Rheumatol. 2008;35:319–326
  82. Yee EFT, White RE, Murata GH, et al. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med. 2007;22:1305–1310
  83. Majumdar SR. Recent trends in osteoporosis treatment after hip fracture: improving but wholly inadequate. J Rheumatol. 2008;35:190–192
  84. Orwoll ES. Treatment of osteoporosis in men. Calcif Tissue Int. 2004;72:114–119
  85. Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:197–213
  86. Tosteson ANA, Melton LJI, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: The United States perspective. Osteoporos Int. 2008;19:437–447
  87. Anonymous. National Osteoporosis Foundation/Fast Facts on Osteoporosis. 2008 (December 12, 2008).
  88. Anonymous . Heart disease and stroke statistics - 2009 update. Circulation. 2009;119:e21–181
  89. Anonymous . 2009 Alzheimer's disease facts and figures. Alzheimer's and Dementia. 2009;5:65
  90. Society AC. American Cancer Society: statistics for 2009, (August 6, 2009. Available at: www.cancer.org/docroot/STT/STT_O.asp).
  91. Binkley N, Gemar D, Woods A, et al. Effect of vitamin D2 or vitamin D3 supplementation on serum 25(OH)D. J Bone Miner Res. 2008;23(suppl 1):S350

PII: S1521-6942(09)00115-6

doi: 10.1016/j.berh.2009.10.001

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 6 , Pages 755-768 , December 2009

Article Tools

* Image Usage & Resolution